BIOMUNEX has a strong IP position. Many priority patent applications cover the platform and products, most of them have been granted. New products and inventions on the BiXAb® technology are covered by additional IP, providing further protection to BIOMUNEX inventions. Various patent applications were filed by BIOMUNEX:
  • several patent applications on the BiXAb® Platform.
  • several patent applications for its BiXAb® lead products with the objective of protecting all BIOMUNEX’ proprietary antibodies.
BIOMUNEX is actively developing new intellectual property based on its own R&D efforts and in collaboration with academic teams and industrial partners. BIOMUNEX notably filed a patent application covering a disruptive novel non-conventional T cell redirection approach for tumor cell killing in collaboration with Curie Institute; this non-conventional T Cell redirection approach could become universal, with the potential to be applied for the treatment of many different oncology indications, both in solid tumors and in hematological malignancies.